- Home
- TCRT vs QLGN Comparison
TCRT vs QLGN Comparison
Compare TCRT & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- QLGN
- Stock Information
- Founded
- TCRT 1998
- QLGN 1996
- Country
- TCRT United States
- QLGN United States
- Employees
- TCRT N/A
- QLGN N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- QLGN Health Care
- Exchange
- TCRT Nasdaq
- QLGN Nasdaq
- Market Cap
- TCRT 3.2M
- QLGN 3.2M
- IPO Year
- TCRT N/A
- QLGN N/A
- Fundamental
- Price
- TCRT $1.80
- QLGN $4.07
- Analyst Decision
- TCRT
- QLGN
- Analyst Count
- TCRT 0
- QLGN 0
- Target Price
- TCRT N/A
- QLGN N/A
- AVG Volume (30 Days)
- TCRT 25.3K
- QLGN 20.7K
- Earning Date
- TCRT 11-14-2024
- QLGN 11-14-2024
- Dividend Yield
- TCRT N/A
- QLGN N/A
- EPS Growth
- TCRT N/A
- QLGN N/A
- EPS
- TCRT N/A
- QLGN N/A
- Revenue
- TCRT $7,000.00
- QLGN N/A
- Revenue This Year
- TCRT N/A
- QLGN N/A
- Revenue Next Year
- TCRT N/A
- QLGN N/A
- P/E Ratio
- TCRT N/A
- QLGN N/A
- Revenue Growth
- TCRT N/A
- QLGN N/A
- 52 Week Low
- TCRT $1.63
- QLGN $3.34
- 52 Week High
- TCRT $33.00
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- TCRT 44.52
- QLGN 45.00
- Support Level
- TCRT $1.67
- QLGN $3.95
- Resistance Level
- TCRT $1.87
- QLGN $4.21
- Average True Range (ATR)
- TCRT 0.15
- QLGN 0.27
- MACD
- TCRT -0.00
- QLGN 0.00
- Stochastic Oscillator
- TCRT 22.41
- QLGN 22.08
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.